This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.
Alumni | RSS | AA | Languages
 
Home > Berater

Pamela J. Yates

Pamela J. Yates

Recognized by her clients as a “terrific oral advocate”* and “superb in court,”* Pamela J. Yates is a highly successful life sciences and product liability trial lawyer who is consistently named one of California’s “Top Women Litigators” and internationally recognized as a “Life Science Star.” Validating these client comments, Pam recently achieved back-to-back victories, including a unanimous defense verdict on behalf of client Philip Morris USA in an Engle progeny case in Florida (Surico v. Philip Morris USA Inc., June 2014), and a major Daubert victory excluding plaintiffs’ general causation expert in complex MDL proceedings on behalf of client Pfizer (In Re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation, June 2014).

MEHR

Pam is one of a very select group of female product liability litigators in the US who has tried cases in multiple state and federal court venues involving pharmaceuticals, consumer products, and medical devices. Pam has extensive experience in MDL and class action work, and for many years has acted as national coordinating counsel in various mass tort cases. In that role, she has been responsible for all aspects of litigation, including trial, trial preparation and strategy, science and overall Daubert strategy.

Successfully defending pharmaceutical companies began early in her career when, as a young associate, Pam drafted the summary judgment in Daubert, leading to the US Supreme Court’s decision that ultimately set the standard for challenging the admissibility of expert testimony. Building on her success in Daubert, Pam’s career has involved significant expert and science related work. For example, Pam led Pfizer’s expert and science teams in defending claims relating to hormone therapy (HT) products and before that, Rezulin and silicone implants. In addition to her science related work on HT products, Pam served as co-lead trial defense counsel in several of the HT matters, securing back-to-back defense verdicts in West Virginia and Connecticut. Pam currently heads up Pfizer’s science team in their defense of Zoloft, including her lead role in a recent Daubert science hearing that resulted in a major victory for the client. 

Pam’s stellar work has garnered significant recognition from a number of industry guides. Notably, Pam was ranked in Chambers USA 2014 for Nationwide: Product Liability & Mass Torts, with clients praising her as a “‘terrific oral advocate’ who ‘delivers high-quality service, top-notch analysis and strategy.’” More recently, she was ranked in The Best Lawyers in America 2015 for Biotechnology Law and Product Liability Litigation, and was previously named in the Litigation and Product Liability Lawyers (2014) Expert Guide by Legal Media Group. Pam is as a member of the team that won Product Liability Practice of the Year for 2013 from Law360, and has been recognized as one of California’s top women litigators in the Daily Journal’s supplement feature, “Top Women Litigators” (2009-2013). Pam was also recently recognized as a “Life Science Star” by Euromoney’s 2013 LMG Life Sciences Guide and has been featured in Who’s Who Legal in the areas of Product Liability Defense (2007, 2008, 2009, 2012 and 2013) and in Life Sciences (2010, 2012 and 2013). In January 2006, Kaye Scholer’s product liability lawyers were awarded The American Lawyer Litigation Product Liability Department of the Year. The award specifically references several successes in the Rezulin litigation, which involved Pam. In August 2005, The National Law Journal’s “The Defense Hot List, sizing up Defense Firms With Big Wins” featured Pam’s defense verdict, discussed below, in a multiple plaintiff products case, In Re Rezulin Litigation.

*Chambers USA 2014, Legal 500 2007

Representative Matters

  • Currently acting as national counsel for Endo Pharmaceuticals Inc. in product liability litigation involving testosterone products regarding claims of heart attack, stroke and related cardiac issues.
  • Currently acting as trial counsel for Philip Morris USA defending Engle class action progeny tobacco cases. On June 6, 2014, Pam achieved a unanimous defense verdict on behalf of Philip Morris USA in an Engle progeny case in Florida. Surico v. Philip Morris USA Inc.
  • Currently acting as lead counsel for the science defense in Zoloft cases for Pfizer Inc. Most recently, Pam was recognized for her thorough cross examination of the plaintiffs’ solo epidemiologist expert in a week-long Daubert hearing. On June 27, 2014, the judge issued an opinion and order excluding all of the scientific options of said expert because the methodology and resulting underlying her opinions were found, by the court, as “not scientifically valid.”, resulting in a huge victory for our client. In Re:  Zoloft (Sertraline) Products Liability Litigation, E.D. Pa.
  • Currently acting as national and local counsel for Endo Pharmaceuticals Inc. and Qualitest in litigation relating to a recall of several oral contraceptive products. Pam is coordinating all phases of the litigation and has led her team to several successes, including defeating two purported class actions.
  • Currently acting as national counsel for Pfizer Inc. in the HT litigation. Responsibilities include acting as lead trial counsel, coordinating and implementing the science defense and handling all phases of litigation, involving several hormone therapy products.
  • In May 2012, Pam, along with Andrew K. Solow (Partner in the New York office), served as co-lead trial counsel for Pfizer units Wyeth, Inc. and Wyeth Pharmaceuticals Inc. in US District Court (Connecticut) and obtained a defense verdict on all counts related to a wrongful death suit involving Wyeth’s hormone therapy (HT) medications Premarin and Prempro. After a three-week trial, the jury dismissed all four of the alleged claims. This decision marks Pam and Andrew’s second win in less than one year regarding both HT medications. Lynn Gardner Moss, et al. v. Wyeth, Inc., et al.
  • In July 2011, Pam, along with Andrew K. Solow, served as trial counsel for Pfizer units, Wyeth Pharmaceuticals Inc. and Pharmacia & Upjohn Co., and obtained a defense verdict in a case involving claims of injuries from the client’s HT medicines. After a three-week trial, the jury found that the HT prescription medicines did not cause the plaintiff’s breast cancer and that the plaintiff’s claims were time-barred by the applicable statute of limitations. Notably, this was the first defense verdict for Pharmacia & Upjohn in the hormone therapy litigation. Hines v. Wyeth, et al.
  • Previously retained as trial counsel for Boehringer Ingelheim defending its blood thinning medicine Pradaxa against product liability lawsuits.
  • The landmark case of Daubert v. Merrell Dow Pharmaceuticals, Inc., 727 F.Supp. 570 (S.D. Cal. 1989); aff’d 951 F.2d 1128 (1991); 509 U.S. 579 (1993). Daubert sets forth the standard by which judges are to act as gatekeepers in excluding “junk science” from the courtroom.
  • Served as national and local counsel for Pfizer Inc. (Warner-Lambert) in the Rezulin (diabetic medication) litigation. Responsibilities covered all aspects of litigation. Pam obtained unanimous defense verdicts against all plaintiffs in the first in the nation consolidated plaintiff trial. All three plaintiffs claimed liver injury from exposure to the medication. This verdict was featured in The National Law Journal’s “The Defense Hot List: Sizing Up Defense Firms with Big Wins” (August 22, 2005).
  • Pam, along with others on the Kaye Scholer team, won an important Daubert victory in the Rezulin multidistrict litigation (2005 WL 583751 (S.D.N.Y.)). After a two-day hearing, the court ruled that plaintiffs could not rely on their proposed expert testimony that Rezulin caused a “silent” liver injury. Pam cross-examined the plaintiffs’ lead toxicologist, which was the focus of the court’s Daubert opinion excluding said testimony.
  • Acted as National Coordinating Counsel in the silicone breast implant litigation, representing Baxter Healthcare Corporation and Baxter International Inc. Responsibilities involved handling all phases of litigation, including trials. Pam obtained defense verdicts in two separate multiple plaintiff trials in Texas. All plaintiffs claimed defective implants due to rupture, negligence, failure to warn, strict liability and fraud. The juries returned defense verdicts on all claims.
  • Represented Wyeth Inc., defending their diet medications Dexfenfluramine and Fenfluramine in the Phen-Fen litigation. Specifically, Pam was responsible for deposing and defending expert witnesses, and developing national experts in the areas of cardiology and pulmonology.
  • Acted as national counsel for Merrell Dow Pharmaceuticals Inc., the manufacturer of Bendectin, an anti-nausea medication for pregnant women. She successfully defended the company against claims of birth defects, ultimately resulting in many courts excluding plaintiff’s expert evidence on the grounds of “junk science,” following her Daubert success.
  • Served as national counsel for pharmaceutical clients in the L-trytophan litigation. Claims involved manufacturing and design defects resulting in Eosinophilia Myalgia Syndrome.
  • Defended heart valves and other implantable medical devices on behalf of Baxter Healthcare Corporation.
  • Defended multiple clients in toxic tort exposure claims.
  • Defended and advised clients in product recalls, including consumer products.

Pro Bono Activities

From 2005-2013, Pam was the Los Angeles partner in charge of pro bono activities, which included tenant disputes with landlords, asylum cases, death penalty cases, victims of home equity fraud and guardian ad litem cases.

Pamela was a finalist in the philanthropy category for her pro bono leadership at the Los Angeles Business Journal’s 2009 “Women Making A Difference” program and ceremony on May 5, 2009.

Pamela was a recipient of the 2007 Wiley W. Manuel Award for Pro Bono legal services awarded by the State Bar of California’s Board of Governors in recognition of her “voluntary provision of legal services to the poor.”

Publications and Presentations

Speaker, “Drug, Device and Biotechnology/Medical Defense: Overcoming Tensions Between Drug/Device Defendants and Treating Physicians,” IADC’s 2014 Midyear Meeting, February 11, 2014.

Co-author, “Overcoming Tensions between Drug/Device Defendants and Treating Physicians,” IADC Midyear Meeting Materials, February 2014.

Speaker, “Strategically Using Daubert in Cross-Examination to Establish Important Defense Themes,” ACI’s 18th Annual Drug & Medical Device Litigation Conference, December 9-11, 2013.

“Is the Doctor In? Litigation Do’s and Don’ts of Contacting Treating Physicians,” Rx for the Defense, October 15, 2013.

Served as a faculty member at the International Association of Defense Counsel’s (IADC) 41st Annual Trial Academy, held at Stanford University, Palo Alto, CA, July 27-August 2, 2013.

“Defending Daubert, 20 years after it was decided,” Los Angeles Daily Journal, June 28, 2013.

Presentation at DRI Drug and Medical Device conference, “The Multiple-Plaintiff Pharmaceutical Trial: Keys to a Successful Defense,” New York, NY, May 2013.

Presentation outline: “Taking the Deposition of the Prescriber: The Trial Lawyer’s Perspective” DRI’s Drug and Medical Device Conference, May 10-11, 2012. Speech given by James Herschlein (Partner, NY office).

“Have You Analyzed Potential Daubert Challenges From All Angles?,” IADC Webinar, March 23, 2011.

Invited panelist at the Southwestern Women’s Law Association “Work Life Balance Panel,”
March 31, 2009.

Speaker, “How Do You Define ‘Design’ in a Design Defect Case,” IADC Mid-Year Meeting 2009, February 2009.

Invited panelist for Daily Journal-sponsored roundtable on product liability, published in the November 2008 issue of California Lawyer.

“Products Liability — Recall Related Evidence,” The National Law Journal, January 28, 2008.

“Take Your Medicine — Recalling a Defective Product Is a Company’s Best Option,” In-House Publication (a Dolan Media publication), January 2008.

Invited panelist for Daily Journal-sponsored roundtable on product liability, published in the December 2007 issue of California Lawyer.

Speaker for multi-venue MCLE presentation titled “Corporate Strategies That Win Jury Trials” for the Association of Corporate Counsel’s in-house counsel members, October 17, 2007.

ABA, Women In Products Liability Conference, Lunchtime Speaker: “There are Trials and You Can Win,” November 17, 2005.

Product Liability Update: “The End of An Era: Lessons to be Learned from the Bendectin Litigation” (1998).

Reported Cases

In Re Rezulin Products Liability Litigation (2005) WL 583751 (S.D.N.Y.).

Daubert v. Merrell Dow Pharmaceuticals, Inc., 727 F.Supp. 570 (S.D. Cal. 1989); aff’d 951 F.2d 1128 (1991); 509 U.S. 579 (1993).

Obiago v. Merrell National Laboratory, Inc., 560 So. 2d 625 (La. App. 4 Cir); writ denied 565 So. 2d 445 (La. 1990).

Personal Information

Pamela was born and raised in England. She represented England in junior tennis matches and came to the US on a tennis scholarship. She is a three time NCAA Women’s Tennis Division II winner as well as a two time recipient of All American Honors. Additionally, Pamela was a recipient of the NCAA Postgraduate Scholarship in recognition of her academic and athletic achievements.

Yates, Pamela

Beratungsschwerpunkte

Ausbildung

Southwestern University School of Law, JD, 1988

University of Tennessee, Chattanooga, BS, cum laude, 1985

Zulassung(en)

California

USDC, Central District of California

USDC, Southern District of California

USDC, Eastern District of California

USDC, Northern District of California

Mitgliedschaften

International Association of Defense Counsel

 
Praxisgruppen Berater Sozietät Careers Diversity Newsroom Veranstaltungen Büros